ReviewJournal of applied clinical medical physics2026
Stereotactic arrhythmia radioablation for refractory ventricular tachycardia: A narrative review and pooled analysis of clinical outcomes and treatment delivery approaches.
Review in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
10 authors.
Funding
Abstract
purposeStereotactic arrhythmia radioablation (STAR) has emerged as a noninvasive salvage therapy for refractory ventricular tachycardia (VT), particularly in patients ineligible for catheter ablation (CA). This narrative review and pooled analysis evaluates STAR's efficacy, safety, and technical characteristics, integrating evidence from preclinical studies, case reports, case series, and clinical trials.
methodsA comprehensive literature search identified 88 studies published between 2015 and 2025, comprising 13 preclinical investigations, 50 case reports, 18 case series, and 7 clinical trials. Study-level data were extracted for pooled analyses of 6- and 12-month mortality, VT burden reduction, and Grade 3+ acute toxicity. Subgroup analyses were performed by delivery modality, age, left ventricular ejection fraction (LVEF), and cardiomyopathy type.
resultsPooled 6- and 12-month mortality were 16% (95% CI: 11%-20%) and 33% (95% CI: 27%-38%), respectively. VT burden reduction at 6 months averaged 75% (95% CI: 73%-77%), with substantial heterogeneity (I
conclusionsSTAR achieves meaningful VT suppression with acceptable acute toxicity across multiple delivery modalities. However, wide inter-study heterogeneity underscores the need for standardized endpoint definitions, dosimetric and motion-management protocols, and prospective follow-up registries. Translational preclinical data and emerging clinical evidence collectively support STAR's continued development as a biologically informed cardiac radiotherapy paradigm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.